Alkeus Pharmaceuticals, Inc.

SOMERVILLE, MA 02144

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $2.25MM
First Award Date 09/01/12
Most Recent Award Date 05/01/17

Key Personnel

Last Name Name Awards Contact
Washington Ilyas Washington 3
SAAD LEONIDE SAAD 2

3 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 05/01/17 - 04/30/18

? DESCRIPTION (provided by applicant): The long-term goal of this work is to develop an oral drug for the prevention of age-related macular degeneration (AMD). AMD is the leading cause of blindness in the United States, with 8 million Americans diagnosed or at risk of irreversibly losing vision, and over 2 million people who already have debi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 05/01/16 - 04/30/17

? DESCRIPTION (provided by applicant): The long-term goal of this work is to develop an oral drug for the prevention of age-related macular degeneration (AMD). AMD is the leading cause of blindness in the United States, with 8 million Americans diagnosed or at risk of irreversibly losing vision, and over 2 million people who already have debil...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 09/01/12 - 08/31/13

DESCRIPTION (provided by applicant): The overall goal of this collaborative research between Alkeus Pharmaceuticals and Columbia University Medical Center is to evaluate a new oral investigational treatment for dry age-related macular degeneration (dry-AMD), the leading cause of blindness in the U.S., and Stargardt's disease, also known as juven...